3 Biotech Stocks That Could More Than Triple if Their Trials Succeed
While the risks remain significant with biotech stocks, the potential rewards could be equally compelling.
Barchart ·
Get all your news in one place.
100's of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100's of premium titles. One news app.
MYSTERIOUS: Avalo - What They Never Told You
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
Avalo Therapeutics (NASDAQ:AVTX) has dosed the first patient in the pivotal LADDER trial to assess the efficacy and safety of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II (LAD II) ER). Avalo shares traded in a range of $3.5 to $3.91 on a day volume of 33.54 thousand shares,…
Benzinga ·
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Coverage From
Benzinga
Barchart
Organisations
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Topics
Read news from The Economist, FT, and more,
with one subscription
with one subscription
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.
100+ trusted global sources.
